Lastly, HOXA9, a transcription factor overexpressed in approximately 70% of AML and associated with poor prognosis, increased chemoresistance, and higher relapse rates, can be successfully inhibited in in vitro human AML models [64]. The gene discussed is HOXA9; the disease is acute myeloid leukemia.